Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001129928-19-000014
Filing Date
2019-03-15
Accepted
2019-03-15 17:21:25
Documents
95
Period of Report
2018-12-31

Document Format Files

Seq Description Document Type Size
1 20-F oncyf2018-20f.htm 20-F 1845606
2 EXHIBIT 8.0 ex80subsidiaries2018.htm EX-8.0 3749
3 EXHIBIT 12.1 ex121ceocertfication2018.htm EX-12.1 13540
4 EXHIBIT 12.2 ex122cfocertification2018.htm EX-12.2 12645
5 EXHIBIT 13.1 ex131ceocertification2018.htm EX-13.1 7094
6 EXHIBIT 13.2 ex132cfocertification2018.htm EX-13.2 5928
7 EXHIBIT 15.1 ex151-2018mda.htm EX-15.1 460007
8 EXHIBIT 15.2 ex152eyconsentletter2018.htm EX-15.2 5287
15 eysignaturea07.jpg GRAPHIC 7648
16 eysignaturea08.jpg GRAPHIC 7648
17 eysignaturea13.jpg GRAPHIC 7648
18 oncolyticslogotaglinebluea02.jpg GRAPHIC 367326
19 pelareorep-lg.jpg GRAPHIC 460603
20 reolysinmoapanel4small.jpg GRAPHIC 148102
  Complete submission text file 0001129928-19-000014.txt   9056248

Data Files

Seq Description Document Type Size
9 XBRL INSTANCE DOCUMENT oncyf-20181231.xml EX-101.INS 1426926
10 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT oncyf-20181231.xsd EX-101.SCH 70013
11 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT oncyf-20181231_cal.xml EX-101.CAL 62731
12 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT oncyf-20181231_def.xml EX-101.DEF 214275
13 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT oncyf-20181231_lab.xml EX-101.LAB 621039
14 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT oncyf-20181231_pre.xml EX-101.PRE 368819
Mailing Address 210 - 1167 KENSINGTON CRES NW CALGARY A0 T2N 1X7
Business Address 1167 KENSINGTON CRES NW SUITE 210 CALGARY ALBERTA CANADA T2N 1X7 ALBERTA CANADA A0 00000 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 001-38512 | Film No.: 19685996
SIC: 2834 Pharmaceutical Preparations